Biosimilars

Biosimilars Market Research Report: Forecast (2022-27)

By Product (Recombinant Non-Glycosylated Proteins (Human growth hormones, Granulocyte colony-stimulating factor, Interferons, Insulin), Recombinant Glycosylated Proteins (Erythropoietin, Monoclonal An Read more

  • Healthcare
  • Jun 2022
  • 182
  • HC22093

Market Definition

Biosimilars are bio-therapeutic products with high similarities to biological drugs. These therapeutics are developed using living organisms or cells and exhibit complex molecular structures. With rapid healthcare developments, Biosimilars are swiftly gaining momentum to address chronic diseases like diabetes, cancer, anemia, and growth hormone deficiency and are becoming globally available. Furthermore, since biosimilars drugs are like the replications of biologics, they are affordable and attract a larger patient pool for various treatments.

Market Insights

The Global Biosimilars Market is projected to grow at a CAGR of around 17% during the forecast period, i.e., 2022-27. The growth of the market is likely to be driven primarily by the growing prevalence of chronic diseases across different corners of the world and the mounting demand for effective & safe medications for their treatments. However, since the treatment cost of various illnesses like cancer is high and restrains numerous patients due to affordability issues, the demand for cost-effective alternatives with similar treatment effects like biologics is rising rapidly and stimulating the growth of the Global Biosimilars Market.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR (2022-2027) 17%
Regions Covered North America: The US, Canada, Mexico
South America: Brazil, Rest of Latin America
Europe: Germany, The UK, France, Spain, Italy, Rest of Europe
Asia-Pacific: China, Japan, India, South East Asia, Rest of Asia Pacific
Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa
Key Companies Profiled Amgen Inc., Biocon, Biogen Inc., Celltrion, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Samsung Bioepis, Others
Unit Denominations USD Million/Billion

 

Besides, governments of different countries are actively participating in the industry through massive expenditure as well as research & development activities for innovations in biosimilar medications to cater to the unmet patient needs for various treatments. In addition, the growing emphasis of the governments on cost-effective drug synthesis to attract a massive patient pool is also contributing to the market expansion.

Furthermore, favorable policies for the development & clinical trials of biosimilars entwined with increasing inclination toward developing new, enhanced, efficient, safe, and affordable therapeutics are also boosting the market, especially across countries like Germany, the UK, France, the US, China, Japan, & India, among others.

Several pharmaceutical companies are undergoing mergers, acquisitions, and collaborations while introducing an extensive range of biosimilars to gain leadership in consumer retention & expand their existing product portfolios.

Nevertheless, regulatory associations like European Medicines Agency, US Food & Drug Administration (FDA), & China Food & Drug Administration have different standards for maintaining the safety profile & effectiveness of biosimilars. As a result, the process of drug approval often becomes time-consuming & lengthy, and it might act as a growth restraint for the Global Biosimilars Market.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Biosimilars Market Trends & Insights
  4. Global Biosimilars Market Regulation & Policy, By Country
  5. Global Biosimilars Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Biosimilars Market Hotspot and Opportunities
  7. Global Biosimilars Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Product
        1. Recombinant Non-Glycosylated Proteins
          1. Human growth hormones
          2. Granulocyte colony-stimulating factor
          3. Interferons
          4. Insulin
        2. Recombinant Glycosylated Proteins
          1. Erythropoietin
          2. Monoclonal Antibodies
          3. Follitropin
      2. By Application
        1. Growth Hormonal Deficiency
        2. Chronic & Autoimmune Disorders
        3. Hematology
        4. Oncology
        5. Others
      3. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      4. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Biosimilars Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Product
      2. By Application
      3. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Biosimilars Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Product
      2. By Application
      3. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Biosimilars Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Product
      2. By Application
      3. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Biosimilars Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Product
      2. By Application
      3. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Biosimilars Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Product
      2. By Application
      3. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Biosimilars Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. Amgen Inc.
      2. Biocon
      3. Biogen Inc.
      4. Celltrion
      5. Dr. Reddy’s Laboratories Ltd
      6. Eli Lilly and Company
      7. F. Hoffmann-La Roche AG
      8. Merck & Co., Inc.
      9. Novartis International AG
      10. Pfizer Inc.
      11. Samsung Bioepis
      12. Others
  15. Disclaimer
Biosimilars Market Segmentation
*This field is required